placeholder image
O. Zerbo All authors
About
Publications While At Healthpartners
selected publications
Journal Article
  • Estimation of COVID-19 mRNA vaccine effectiveness and COVID-19 illness and severity by vaccination status during Omicron BA.4 and BA.5 sublineage periods. 
    JAMA network open. 2023
  • Protection of two and three mRNA vaccine doses against severe outcomes among adults hospitalized with COVID-19-VISION Network, August 2021 to March 2022. 
    Journal of Infectious Diseases. 2023
  • Relationships between social vulnerability and coronavirus disease 2019 vaccination coverage and vaccine effectiveness. 
    Clinical Infectious Diseases. 2023
  • Changes in incidence rates of outcomes of interest in vaccine safety studies during the COVID-19 pandemic. 
    Vaccine. 2022
  • Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19-associated emergency department or urgent care encounters and hospitalizations among immunocompetent adults - VISION Network, nine states, September-November 2022. 
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of 2, 3, and 4 COVID-19 mRNA vaccine doses among immunocompetent adults during periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 sublineages predominated - VISION Network, 10 states, December 2021-June 2022. 
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA vaccination in preventing COVID-19-associated emergency department and urgent care encounters and hospitalizations among nonimmunocompromised children and adolescents aged 5-17 years - VISION Network, 10 states, April 2021-January 2022. 
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of COVID-19 mRNA vaccines against COVID-19-associated hospitalizations among immunocompromised adults during SARS-CoV-2 Omicron predominance - VISION Network, 10 states, December 2021-August 2022. 
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of a third dose of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during oeriods of Delta and Omicron variant predominance - VISION Network, 10 states, August 2021-January 2022. 
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of homologous and heterologous COVID-19 booster doses following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) vaccine dose against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults - VISION Network, 10 states, December 2021-March 2022. 
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults-nine states, January-September 2021. 
    American Journal of Transplantation. 2022
  • Estimation of COVID-19 mRNA vaccine effectiveness against medically attended COVID-19 in pregnancy during periods of Delta and Omicron variant predominance in the United States. 
    JAMA network open. 2022
  • Evaluation of acute adverse events after Covid-19 vaccination during pregnancy. 
    New England Journal of Medicine. 2022
  • Health care utilization in the 6 months following SARS-CoV-2 infection. 
    JAMA network open. 2022
  • Kawasaki disease following the 13-valent pneumococcal conjugate vaccine and rotavirus vaccines. 
    Pediatrics. 2022
  • Receipt of COVID-19 vaccine during pregnancy and preterm or small-for-gestational-age at birth - eight integrated health care organizations, United States, December 15, 2020-July 22, 2021. 
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination. 
    Vaccine. 2022
  • Safety of COVID-19 vaccination in United States children ages 5 to 11 years. 
    Pediatrics. 2022
  • Safety of live-attenuated vaccines in children exposed to biologic response modifiers in utero. 
    Pediatrics. 2022
  • Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance - VISION Network, 10 states, August 2021-January 2022. 
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study. 
    BMJ (Clinical research ed.). 2022
  • COVID-19 vaccination coverage among insured persons aged ≥16 years, by race/ethnicity and other selected characteristics - eight integrated health care organizations, United States, December 14, 2020-May 15, 2021. 
    MMWR: Morbidity and Mortality Weekly Report. 2021
  • COVID-19 vaccination coverage among pregnant women during pregnancy - eight integrated health care organizations, United States, December 14, 2020-May 8, 2021. 
    MMWR: Morbidity and Mortality Weekly Report. 2021
  • Effectiveness of 2-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults - nine states, January-September 2021. 
    MMWR: Morbidity and Mortality Weekly Report. 2021
  • Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings. 
    New England Journal of Medicine. 2021
  • Laboratory-confirmed COVID-19 among adults hospitalized with COVID-19-like illness with infection-induced or mRNA vaccine-induced SARS-CoV-2 immunity - nine states, January-September 2021. 
    MMWR: Morbidity and Mortality Weekly Report. 2021
  • Surveillance for adverse events after COVID-19 mRNA vaccination. 
    JAMA. 2021
  • Vaccine Safety Datalink infrastructure enhancements for evaluating the safety of maternal vaccination. 
    Therapeutic advances in drug safety. 2021
  • Order of live and inactivated vaccines and risk of non-vaccine-targeted infections in US children 11-23 months of age. 
    Pediatric Infectious Disease Journal. 2020
  • Risk for subdeltoid bursitis after influenza vaccination: a population-based cohort study. 
    Annals of Internal Medicine. 2020
  • Association between estimated cumulative vaccine antigen exposure through the first 23 months of life and non-vaccine-targeted infections from 24 through 47 months of age. 
    JAMA. 2018
    • Contact
    full name
  • O. Zerbo
    • Quick Info
     
    Collaboration